BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843-854. [PMID: 21844879 DOI: 10.1038/ijo.2011.158] [Cited by in Crossref: 393] [Cited by in F6Publishing: 433] [Article Influence: 35.7] [Reference Citation Analysis]
Number Citing Articles
1 De la Rosa A, Ghusn W, Sacoto D, Campos A, Cifuentes L, Feris F, Busebee B, Calderon G, Acosta A, Hurtado MD. A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center. Obesity Pillars 2022. [DOI: 10.1016/j.obpill.2022.100046] [Reference Citation Analysis]
2 Tham KW, Abdul Ghani R, Cua SC, Deerochanawong C, Fojas M, Hocking S, Lee J, Nam TQ, Pathan F, Saboo B, Soegondo S, Somasundaram N, Yong AML, Ashkenas J, Webster N, Oldfield B. Obesity in South and Southeast Asia—A new consensus on care and management. Obesity Reviews 2022. [DOI: 10.1111/obr.13520] [Reference Citation Analysis]
3 Vigil P, Meléndez J, Petkovic G, Del Río JP. The importance of estradiol for body weight regulation in women. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.951186] [Reference Citation Analysis]
4 Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P; AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology 2022;163:1198-225. [PMID: 36273831 DOI: 10.1053/j.gastro.2022.08.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wen ZG, Zhang QQ, Zhang LL, Shen MF, Huang YS, Zhao LH. Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis. Front Pharmacol 2022;13:964495. [DOI: 10.3389/fphar.2022.964495] [Reference Citation Analysis]
6 Idrees Z, Cancarevic I, Huang L. FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade. Cureus 2022. [DOI: 10.7759/cureus.29262] [Reference Citation Analysis]
7 Liao Y, Chen H, Yang C, Lee P, Hsu C, Huang Y, Yang T. Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study. Front Pharmacol 2022;13:978814. [DOI: 10.3389/fphar.2022.978814] [Reference Citation Analysis]
8 Rutledge C, Redding K, Lopez M, Mullett S, Wendell S, Jurczak M, Goetzman E, Kaufman B. Liraglutide protects against diastolic dysfunction and improves ventricular protein translation.. [DOI: 10.1101/2022.08.23.504997] [Reference Citation Analysis]
9 Cases A. Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo. Nefrología 2022. [DOI: 10.1016/j.nefro.2022.07.008] [Reference Citation Analysis]
10 Reid TJ, Korner J. Medical and Surgical Treatment of Obesity. Medical Clinics of North America 2022. [DOI: 10.1016/j.mcna.2022.03.002] [Reference Citation Analysis]
11 Agius R, Coelho C, Mcgowan B. GLP-1 analogues in clinical management of obesity. Current Opinion in Endocrine and Metabolic Research 2022;25:100360. [DOI: 10.1016/j.coemr.2022.100360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Deng Y, Park A, Zhu L, Xie W, Pan CQ. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Ther Adv Chronic Dis 2022;13:20406223221108064. [PMID: 35813188 DOI: 10.1177/20406223221108064] [Reference Citation Analysis]
13 Park H, Huh Y, Kim SH, Yoo M, Ko CS, Park HS. Longitudinal Changes of Body Weight According to Sex∙Age and Metabolic Parameters in Korean Morbid Obese Patients after Sleeve Gastrectomy: 12-Month Retrospective Cohort Study. Korean J Fam Pract 2022;12:185-192. [DOI: 10.21215/kjfp.2022.12.3.185] [Reference Citation Analysis]
14 Elhag W, El Ansari W. Medical Weight Management: A Multidisciplinary Approach. Weight Management - Challenges and Opportunities [Working Title] 2022. [DOI: 10.5772/intechopen.105475] [Reference Citation Analysis]
15 Tchang BG, Aras M, Wu A, Aronne LJ, Shukla AP. Long‐term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study. Obesity Science & Practice 2022;8:320-327. [DOI: 10.1002/osp4.575] [Reference Citation Analysis]
16 Taha MB, Yahya T, Satish P, Laird R, Agatston AS, Cainzos-Achirica M, Patel KV, Nasir K. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Curr Atheroscler Rep 2022. [PMID: 35624390 DOI: 10.1007/s11883-022-01041-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Alabduljabbar K, Al-Najim W, le Roux CW. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients 2022;14:2217. [PMID: 35684020 DOI: 10.3390/nu14112217] [Reference Citation Analysis]
18 Barboza JJ, Huamán MR, Melgar B, Diaz-Arocutipa C, Valenzuela-Rodriguez G, Hernandez AV. Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2022;11:2998. [PMID: 35683387 DOI: 10.3390/jcm11112998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 O'connor RM, Kenny PJ. Utility of ‘substance use disorder’ as a heuristic for understanding overeating and obesity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022. [DOI: 10.1016/j.pnpbp.2022.110580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Danowitz M, De Leon DD. The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. Front Endocrinol 2022;13:863184. [DOI: 10.3389/fendo.2022.863184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Al‐bazz D, Wilding JP. Adjunctive Therapy, Including Pharmacotherapy. Clinical Obesity in Adults and Children 2022. [DOI: 10.1002/9781119695257.ch21] [Reference Citation Analysis]
22 Sumińska M, Podgórski R, Bogusz-Górna K, Skowrońska B, Mazur A, Fichna M. Historical and cultural aspects of obesity: From a symbol of wealth and prosperity to the epidemic of the 21st century. Obes Rev 2022;:e13440. [PMID: 35238142 DOI: 10.1111/obr.13440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Mashayekhi M, Beckman JA, Nian H, Garner EM, Mayfield D, Wright P, Howard SE, Perkins B, Olson D, Snyder WE, Devin JK, Koethe JR, Brown JD, Cahill KN, Yu C, Silver H, Niswender K, Luther JM, Brown NJ. Comparative Effects of Weight Loss and Incretin-Based Therapies on Vascular Endothelial Function, Fibrinolysis, and Inflammation: A Randomized, Controlled Trial.. [DOI: 10.1101/2022.02.23.22271434] [Reference Citation Analysis]
24 Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, Zhou HD. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev 2022;:e13435. [PMID: 35194917 DOI: 10.1111/obr.13435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Volcko K, Brakey D, Mcnamara T, Meyer M, Mckay N, Santollo J, Daniels D. Control of water intake by a pathway from the nucleus of the solitary tract to the paraventricular hypothalamic nucleus. Appetite 2022. [DOI: 10.1016/j.appet.2022.105943] [Reference Citation Analysis]
26 Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022;327:138-50. [PMID: 35015037 DOI: 10.1001/jama.2021.23619] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 38.0] [Reference Citation Analysis]
27 Bandeira F, Moura F, Costi BB, Cardoso ACSM. GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. Endocrinology and Diabetes 2022. [DOI: 10.1007/978-3-030-90684-9_31] [Reference Citation Analysis]
28 Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083-91. [PMID: 36216945 DOI: 10.1038/s41591-022-02026-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Dinda B, Saha S. Obesity and Diabetes. Natural Products in Obesity and Diabetes 2022. [DOI: 10.1007/978-3-030-92196-5_1] [Reference Citation Analysis]
30 Alarfaj SJ, Ibrahim A, Alshahrani J, Alnuwaysir M, Almutairi A, Alwahhabi B. Effectiveness, tolerability, and pattern of liraglutide treatment use for weight loss: a mixed-methods cohort study. J Adv Pharm Educ Res 2022;12:63-70. [DOI: 10.51847/wav0cpt0bt] [Reference Citation Analysis]
31 Mundi MS, Collazo-clavell ML. Treatment of Obesity in the Patient with Type 2 Diabetes. Endocrinology and Diabetes 2022. [DOI: 10.1007/978-3-030-90684-9_43] [Reference Citation Analysis]
32 Jagasia S, Hendrickson CD, Williams AJ. Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus. Clinical Dilemmas in Diabetes 2021. [DOI: 10.1002/9781119603207.ch15] [Reference Citation Analysis]
33 Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the Treatment of Obesity. Trends Cardiovasc Med 2021:S1050-1738(21)00158-4. [PMID: 34942372 DOI: 10.1016/j.tcm.2021.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Zhang W, Li M, Zan Y, Bai Y. Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Like Agonist, Exendin-4-Fc. Int J Pept Res Ther 2021;27:2517-2526. [DOI: 10.1007/s10989-021-10269-x] [Reference Citation Analysis]
35 Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 2021. [PMID: 34815532 DOI: 10.1038/s41573-021-00337-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 83] [Article Influence: 65.0] [Reference Citation Analysis]
36 Calderon G, Gonzalez-Izundegui D, Shan KL, Garcia-Valencia OA, Cifuentes L, Campos A, Collazo-Clavell ML, Shah M, Hurley DL, Abu Lebdeh HS, Sharma M, Schmitz K, Clark MM, Grothe K, Mundi MS, Camilleri M, Abu Dayyeh BK, Hurtado Andrade MD, Mokadem MA, Acosta A. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes (Lond) 2021. [PMID: 34811486 DOI: 10.1038/s41366-021-01019-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Shepard BD, Ecelbarger CM. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Semin Nephrol 2021;41:331-48. [PMID: 34715963 DOI: 10.1016/j.semnephrol.2021.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Del Prato S, Gallwitz B, Holst JJ, Meier JJ. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obes Rev 2021. [PMID: 34713962 DOI: 10.1111/obr.13372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocr Rev 2021:bnab034. [PMID: 34698815 DOI: 10.1210/endrev/bnab034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
40 Smith KR, Moran TH. Gastrointestinal peptides in eating-related disorders. Physiol Behav 2021;238:113456. [PMID: 33989649 DOI: 10.1016/j.physbeh.2021.113456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
41 Yuan F, Latif MA, Shafaat O, Prologo JD, Hill JO, Gudzune KA, Marrone AK, Kraitchman DL, Rogers AM, Khaitan L, Oklu R, Pereira K, Steele K, White SB, Weiss CR. Interventional Radiology Obesity Therapeutics: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. J Vasc Interv Radiol 2021;32:1388.e1-1388.e14. [PMID: 34462083 DOI: 10.1016/j.jvir.2021.05.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Hartinger JM. Novel drugs in pharmacotherapy of obesity. Prakticke lekarenstvi 2021;17:74-80. [DOI: 10.36290/lek.2021.015] [Reference Citation Analysis]
43 Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, Rodder S, Pandey A, Joshi PH. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol 2021;9:595-605. [PMID: 34358471 DOI: 10.1016/S2213-8587(21)00179-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
44 Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther 2021;38:2821-39. [PMID: 33977495 DOI: 10.1007/s12325-021-01710-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
45 Gilijamse PW, Demirkiran A, van Wagensveld BA, Ackermans MT, Romijn JA, Nieuwdorp M, Ter Horst KW, Serlie MJ. The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity. Surg Obes Relat Dis 2021;17:1440-8. [PMID: 34083134 DOI: 10.1016/j.soard.2021.04.022] [Reference Citation Analysis]
46 Pirlet C, Poirier P, Cieza T, Piché ME, Biertho L, Maes F, Ruzsa Z, Bertrand OF. Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. Am J Cardiovasc Drugs 2021;21:271-81. [PMID: 32812206 DOI: 10.1007/s40256-020-00428-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Lee JF, Berzan E, Sridhar VS, Odutayo A, Cherney DZI. Cardiorenal Protection in Diabetic Kidney Disease. Endocrinol Metab (Seoul) 2021;36:256-69. [PMID: 33873265 DOI: 10.3803/EnM.2021.987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
48 Jones S, Luo S, Dorton HM, Yunker AG, Angelo B, Defendis A, Monterosso JR, Page KA. Obesity and Dietary Added Sugar Interact to Affect Postprandial GLP-1 and Its Relationship to Striatal Responses to Food Cues and Feeding Behavior. Front Endocrinol (Lausanne) 2021;12:638504. [PMID: 33868172 DOI: 10.3389/fendo.2021.638504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
49 Casey R, Adelfio A, Connolly M, Wall A, Holyer I, Khaldi N. Discovery through Machine Learning and Preclinical Validation of Novel Anti-Diabetic Peptides. Biomedicines 2021;9:276. [PMID: 33803471 DOI: 10.3390/biomedicines9030276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
50 Gudbergsen H, Overgaard A, Henriksen M, Wæhrens EE, Bliddal H, Christensen R, Nielsen SM, Boesen M, Knop FK, Astrup A, Rasmussen MU, Bartholdy C, Daugaard CL, Ellegaard K, Heitmann BL, Bartels EM, Danneskiold-Samsøe B, Kristensen LE. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr 2021;113:314-23. [PMID: 33471039 DOI: 10.1093/ajcn/nqaa328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
51 Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes (Lond) 2021;45:1249-58. [PMID: 33658682 DOI: 10.1038/s41366-021-00788-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 21.0] [Reference Citation Analysis]
52 Gill L, Mackey S. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. J Womens Health (Larchmt) 2021;30:1016-27. [PMID: 33626287 DOI: 10.1089/jwh.2020.8683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Pasquel FJ, Urrutia MA, Cardona S, Coronado KWZ, Albury B, Perez-Guzman MC, Galindo RJ, Chaudhuri A, Iacobellis G, Palacios J, Farias JM, Gomez P, Anzola I, Vellanki P, Fayfman M, Davis GM, Migdal AL, Peng L, Umpierrez GE. Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge. Diabetes Obes Metab 2021;23:1351-60. [PMID: 33591621 DOI: 10.1111/dom.14347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
54 Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab 2020;105:dgaa285. [PMID: 32442310 DOI: 10.1210/clinem/dgaa285] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 39.0] [Reference Citation Analysis]
55 Das G. Liraglutide for overweight and obesity. Pract Diab 2021;38:7. [DOI: 10.1002/pdi.2313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Smollich M. Abnehmen mit Arzneimitteln? Pharmakotherapie von Übergewicht und Adipositas. Aktuelle Ernährungsmedizin 2021;46:41-55. [DOI: 10.1055/a-1118-2562] [Reference Citation Analysis]
57 Wharton S, Astrup A, Endahl L, Lean MEJ, Satylganova A, Skovgaard D, Wadden TA, Wilding JPH. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. Int J Obes (Lond) 2021;45:923-33. [PMID: 33462358 DOI: 10.1038/s41366-020-00733-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
58 Larsen AT, Gydesen S, Sonne N, Karsdal MA, Henriksen K. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. BMC Endocr Disord 2021;21:10. [PMID: 33413317 DOI: 10.1186/s12902-020-00678-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
59 Yan H, Wu W, Chang X, Xia M, Ma S, Wang L, Gao J. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ 2021;12:1. [PMID: 33397443 DOI: 10.1186/s13293-020-00344-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
60 Molchanova O. A modern view on the prevention and treatment of arterial hypertension in obesity. Profil med 2021;24:97. [DOI: 10.17116/profmed20212406197] [Reference Citation Analysis]
61 邢 国. Research Progress of Liraglutide in Improving Obesity. ACM 2021;11:5501-5506. [DOI: 10.12677/acm.2021.1111814] [Reference Citation Analysis]
62 Bray GA. Therapeutic Management of Obesity. Contemporary Cardiology 2021. [DOI: 10.1007/978-3-030-56514-5_17] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Gorain B, Choudhury H, Sengupta P, Verma RK, Pandey M. Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity. Obesity and its Impact on Health 2021. [DOI: 10.1007/978-981-33-6408-0_10] [Reference Citation Analysis]
64 Son JW, Kim S. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes Metab J 2020;44:802-18. [PMID: 33389955 DOI: 10.4093/dmj.2020.0258] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
65 Clasen MM, Riley AL, Davidson TL. Hippocampal-Dependent Inhibitory Learning and Memory Processes in the Control of Eating and Drug Taking. Curr Pharm Des 2020;26:2334-52. [PMID: 32026771 DOI: 10.2174/1381612826666200206091447] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
66 Fitch A, Ingersoll AB. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers. Postgrad Med 2021;133:310-9. [PMID: 33151791 DOI: 10.1080/00325481.2020.1845534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Perez-Montes DE Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol (Torino) 2021;46:168-76. [PMID: 33213122 DOI: 10.23736/S2724-6507.20.03369-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
68 Werida R, Kabel M, Omran G, Shokry A, Mostafa T. Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. Diabetes Res Clin Pract 2020;170:108473. [PMID: 33002553 DOI: 10.1016/j.diabres.2020.108473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Papaetis GS. Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence. Curr Diabetes Rev 2020;16:699-715. [PMID: 31886752 DOI: 10.2174/1573399816666191230113446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
70 Chao AM, Wadden TA, Berkowitz RI, Quigley K, Silvestry F. The risk of cardiovascular complications with current obesity drugs. Expert Opin Drug Saf 2020;19:1095-104. [PMID: 32750250 DOI: 10.1080/14740338.2020.1806234] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
71 Williams DM, Evans M. Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies. Diabetes Ther 2020;11:2221-35. [PMID: 32880877 DOI: 10.1007/s13300-020-00917-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
72 Molocea CE, Tsokanos FF, Herzig S. Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies. Curr Opin Pharmacol 2020;53:101-16. [PMID: 32871469 DOI: 10.1016/j.coph.2020.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Дыдышко Ю, Шепелькевич А. Obesity: Current Treatment Options in Adults. Рецепт 2020. [DOI: 10.34883/pi.2020.2.2.041] [Reference Citation Analysis]
74 Ferrari F, Fierabracci P, Salvetti G, Jaccheri R, Vitti J, Scartabelli G, Meola A, Magno S, Ceccarini G, Santini F. Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center. J Endocrinol Invest 2020;43:1779-85. [PMID: 32594453 DOI: 10.1007/s40618-020-01334-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
75 Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul) 2019;34:247-62. [PMID: 31565876 DOI: 10.3803/EnM.2019.34.3.247] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 12.5] [Reference Citation Analysis]
76 Abdul-Ghani MA, Jayyousi A, DeFronzo RA, Asaad N, Al-Suwaidi J. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications. Curr Vasc Pharmacol 2019;17:153-63. [PMID: 29032755 DOI: 10.2174/1570161115666171010115119] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
77 Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, Taveras EM, Corey K, Kaplan L, Hur C. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract 2020;6:162-70. [PMID: 32313674 DOI: 10.1002/osp4.390] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
78 Williams DM, Nawaz A, Evans M. Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Ther 2020;11:1199-216. [PMID: 32297119 DOI: 10.1007/s13300-020-00816-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 37.0] [Reference Citation Analysis]
79 Stirban OA, Horbach T. Adipositas- und Metabolische Chirurgie als Option im Konzept gegen Diabetes. Info Diabetol 2020;14:35-44. [DOI: 10.1007/s15034-020-2111-4] [Reference Citation Analysis]
80 Kaji N, Takagi Y, Matsuda S, Takahashi A, Fujio S, Asai F. Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high-fat diet. Animal Model Exp Med 2020;3:62-8. [PMID: 32318661 DOI: 10.1002/ame2.12106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
81 Kondrashina A, Brodkorb A, Giblin L. Dairy-derived peptides for satiety. Journal of Functional Foods 2020;66:103801. [DOI: 10.1016/j.jff.2020.103801] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
82 Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract 2020;26:107-39. [PMID: 32022600 DOI: 10.4158/CS-2019-0472] [Cited by in Crossref: 257] [Cited by in F6Publishing: 267] [Article Influence: 128.5] [Reference Citation Analysis]
83 May M, Schindler C, Engeli S. Modern pharmacological treatment of obese patients. Ther Adv Endocrinol Metab 2020;11:2042018819897527. [PMID: 32030121 DOI: 10.1177/2042018819897527] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
84 Cantini G, Trabucco M, Dicembrini I, Mannucci E, Luconi M. Intestinal Hormones. Hormonal Signaling in Biology and Medicine 2020. [DOI: 10.1016/b978-0-12-813814-4.00016-x] [Reference Citation Analysis]
85 Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol 2020;13:53-64. [PMID: 31770497 DOI: 10.1080/17512433.2020.1698291] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 18.7] [Reference Citation Analysis]
86 van Eyk HJ, Paiman EHM, Bizino MB, IJzermans SL, Kleiburg F, Boers TGW, Rappel EJ, Burakiewicz J, Kan HE, Smit JWA, Lamb HJ, Jazet IM, Rensen PCN. Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2020;30:616-24. [PMID: 32127340 DOI: 10.1016/j.numecd.2019.12.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
87 English A, Irwin N. Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions. Clin Med Insights Endocrinol Diabetes 2019;12:1179551419888871. [PMID: 32425629 DOI: 10.1177/1179551419888871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Lin CH, Shao L, Zhang YM, Tu YJ, Zhang Y, Tomlinson B, Chan P, Liu Z. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother 2020;21:275-85. [PMID: 31790314 DOI: 10.1080/14656566.2019.1695779] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
89 Shiraki A, Oyama JI, Nishikido T, Node K. GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy. Cardiovasc Diabetol 2019;18:164. [PMID: 31779634 DOI: 10.1186/s12933-019-0966-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
90 Li X, Bello NT. Anorectic state of obesity medications in the United States. Are leaner times ahead? Expert Opin Pharmacother 2020;21:167-72. [PMID: 31762335 DOI: 10.1080/14656566.2019.1692815] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Liao T, Zhang SL, Yuan X, Mo WQ, Wei F, Zhao SN, Yang W, Liu H, Rong X. Liraglutide Lowers Body Weight Set Point in DIO Rats and its Relationship with Hypothalamic Microglia Activation. Obesity (Silver Spring) 2020;28:122-31. [PMID: 31773909 DOI: 10.1002/oby.22666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
92 Bretón-Romero R, Weisbrod RM, Feng B, Holbrook M, Ko D, Stathos MM, Zhang JY, Fetterman JL, Hamburg NM. Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus. J Am Heart Assoc 2018;7:e009379. [PMID: 30371206 DOI: 10.1161/JAHA.118.009379] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
93 Tchang BG, Abel B, Zecca C, Saunders KH, Shukla AP. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity. Expert Opinion on Pharmacotherapy 2020;21:21-8. [DOI: 10.1080/14656566.2019.1685496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
94 Wharton S, Liu A, Pakseresht A, Nørtoft E, Haase CL, Mancini J, Power GS, Vanderlelie S, Christensen RAG. Response to “Liraglutide Effectiveness: Is There a Real‐World Clinical Benefit?”. Obesity 2019;27:1728-1728. [DOI: 10.1002/oby.22630] [Reference Citation Analysis]
95 Bodnaruc AM, Prud'homme D, Giroux I. Acute effects of an isocaloric macronutrient-matched breakfast meal containing almonds on glycemic, hormonal, and appetite responses in men with type 2 diabetes: a randomized crossover study. Appl Physiol Nutr Metab 2020;45:520-9. [PMID: 31618605 DOI: 10.1139/apnm-2019-0559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
96 Gorky J, Schwaber J. Conceptualization of a Parasympathetic Endocrine System. Front Neurosci 2019;13:1008. [PMID: 31607849 DOI: 10.3389/fnins.2019.01008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. Afr Health Sci 2019;19:2591-9. [PMID: 32127832 DOI: 10.4314/ahs.v19i3.35] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
98 Gorgojo‐martínez JJ, Basagoiti‐carreño B, Sanz‐velasco A, Serrano‐moreno C, Almodóvar‐ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real‐world setting: The XENSOR Study. Int J Clin Pract 2019;73. [DOI: 10.1111/ijcp.13399] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
99 Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med 2019;7:393. [PMID: 31555707 DOI: 10.21037/atm.2019.07.27] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
100 Aldekhail NM, Morrison DS, Khojah H, Sloan B, McLoone P, MacNaughton S, Shearer R, Logue J. The association between diabetes medication and weight change in a non-surgical weight management intervention: an intervention cohort study. Diabet Med 2020;37:248-55. [PMID: 31365143 DOI: 10.1111/dme.14093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
101 Rubio Herrera MA, Fernández-García JM, Corio Andújar R, Santos Altozano C, Urieta Carpi JJ. [Pharmacological treatment of obesity for Primary Care physicians]. Semergen 2019;45:559-65. [PMID: 31350172 DOI: 10.1016/j.semerg.2019.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
102 González-García I, Milbank E, Diéguez C, López M, Contreras C. Glucagon, GLP-1 and Thermogenesis. Int J Mol Sci 2019;20:E3445. [PMID: 31337027 DOI: 10.3390/ijms20143445] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
103 Gouni-Berthold I, Berthold HK. Current Options for the Pharmacotherapy of Obesity. Curr Pharm Des 2019;25:2019-32. [PMID: 31298150 DOI: 10.2174/1381612825666190708192630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
104 Boutari C, Polyzos SA, Mantzoros CS. Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it? Metabolism 2019;96:vi-xi. [DOI: 10.1016/j.metabol.2019.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
105 Liberini CG, Koch-Laskowski K, Shaulson E, McGrath LE, Lipsky RK, Lhamo R, Ghidewon M, Ling T, Stein LM, Hayes MR. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss. Sci Rep 2019;9:8447. [PMID: 31186439 DOI: 10.1038/s41598-019-44591-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
106 Rao S, Pandey A, Garg S, Park B, Mayo H, Després JP, Kumbhani D, de Lemos JA, Neeland IJ. Effect of Exercise and Pharmacological Interventions on Visceral Adiposity: A Systematic Review and Meta-analysis of Long-term Randomized Controlled Trials. Mayo Clin Proc 2019;94:211-24. [PMID: 30711119 DOI: 10.1016/j.mayocp.2018.09.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
107 Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs 2018;78:1113-32. [PMID: 30014268 DOI: 10.1007/s40265-018-0946-y] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 21.3] [Reference Citation Analysis]
108 Vasanth Rao VRB, Candasamy M, Bhattamisra SK. Obesity an overview: Genetic conditions and recent developments in therapeutic interventions. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:2112-20. [DOI: 10.1016/j.dsx.2019.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
109 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract 2019;25:69-100. [PMID: 30742570 DOI: 10.4158/CS-2018-0535] [Cited by in Crossref: 199] [Cited by in F6Publishing: 219] [Article Influence: 66.3] [Reference Citation Analysis]
110 Neeland IJ, Poirier P, Després JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation 2018;137:1391-406. [PMID: 29581366 DOI: 10.1161/CIRCULATIONAHA.117.029617] [Cited by in Crossref: 328] [Cited by in F6Publishing: 343] [Article Influence: 109.3] [Reference Citation Analysis]
111 Christensen RM, Juhl CR, Torekov SS. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. Drug Saf 2019;42:957-71. [DOI: 10.1007/s40264-019-00812-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
112 Yehya A, Sadhu AR. New Therapeutic Strategies for Type 2 Diabetes CME. Methodist Debakey Cardiovasc J 2018;14:281-8. [PMID: 30788014 DOI: 10.14797/mdcj-14-4-281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
113 Meneguetti BT, Cardoso MH, Ribeiro CF, Felício MR, Pinto IB, Santos NC, Carvalho CM, Franco OL. Neuropeptide receptors as potential pharmacological targets for obesity. Pharmacology & Therapeutics 2019;196:59-78. [DOI: 10.1016/j.pharmthera.2018.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
114 Tronieri JS, Wadden TA, Walsh O, Berkowitz RI, Alamuddin N, Gruber K, Leonard S, Bakizada ZM, Chao AM. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. Int J Obes (Lond) 2020;44:353-61. [PMID: 30926955 DOI: 10.1038/s41366-019-0348-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
115 Tuttle KR, Lakshmanan MC, Rayner B, Zimmermann AG, Woodward B, Botros FT. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Diabetes Obes Metab 2019;21:1493-7. [PMID: 30762290 DOI: 10.1111/dom.13668] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
116 Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, Desai J, Fitzpatrick SL, Horberg M, Koebnick C, Oshiro C, Yamamoto A, Young DR, Arterburn DE. Safety and Effectiveness of Longer‐Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. Obesity 2019;27:591-602. [DOI: 10.1002/oby.22430] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
117 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 350] [Cited by in F6Publishing: 382] [Article Influence: 116.7] [Reference Citation Analysis]
118 Bułdak Ł, Machnik G, Skudrzyk E, Bołdys A, Okopień B. The impact of exenatide (a GLP-1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Exp Ther Med 2019;17:2861-9. [PMID: 30906473 DOI: 10.3892/etm.2019.7245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
119 Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord 2019;19:4. [PMID: 30616638 DOI: 10.1186/s12902-018-0332-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
120 Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocr Rev. 2018;39:79-132. [PMID: 29518206 DOI: 10.1210/er.2017-00253] [Cited by in Crossref: 346] [Cited by in F6Publishing: 364] [Article Influence: 115.3] [Reference Citation Analysis]
121 Wharton S, Costanian C, Gershon T, Christensen RAG. Obesity and Diabetes. The Diabetes Textbook 2019. [DOI: 10.1007/978-3-030-11815-0_39] [Reference Citation Analysis]
122 Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides 2019;111:26-32. [DOI: 10.1016/j.peptides.2018.09.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
123 Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand 2019;139:26-36. [PMID: 30374965 DOI: 10.1111/acps.12982] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
124 Mesures hygiéno-diététiques et états diabétiques. Diabetologie 2019. [DOI: 10.1016/b978-2-294-75889-8.00006-3] [Reference Citation Analysis]
125 Brett EM. Pharmacotherapy for Weight Management. Bariatric Endocrinology 2019. [DOI: 10.1007/978-3-319-95655-8_21] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Gibbons C, Blundell JE. Quantifying Appetite and Satiety. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease 2019. [DOI: 10.1007/978-3-030-11748-1_5] [Reference Citation Analysis]
127 Dang JT, Switzer N, Sun WYL, Raghavji F, Birch DW, Karmali S. Authers' Response. Surg Obes Relat Dis 2019;15:155-7. [PMID: 30573302 DOI: 10.1016/j.soard.2018.11.007] [Reference Citation Analysis]
128 Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:k4880. [PMID: 30518618 DOI: 10.1136/bmj.k4880] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
129 Liberini CG, Lhamo R, Ghidewon M, Ling T, Juntereal N, Chen J, Cao A, Stein LM, Hayes MR. Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats. Diabetes Obes Metab 2019;21:866-75. [PMID: 30456866 DOI: 10.1111/dom.13591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
130 Wadden TA, Walsh OA, Berkowitz RI, Chao AM, Alamuddin N, Gruber K, Leonard S, Mugler K, Bakizada Z, Tronieri JS. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. Obesity (Silver Spring) 2019;27:75-86. [PMID: 30421856 DOI: 10.1002/oby.22359] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
131 Kondrashina A, Seratlic S, Kandil D, Treguier N, Kilcawley K, Schellekens H, Beresford T, Giblin L. Irish Cheddar cheese increases glucagon-like peptide-1 secretion in vitro but bioactivity is lost during gut transit. Food Chemistry 2018;265:9-17. [DOI: 10.1016/j.foodchem.2018.05.062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
132 Basolo A, Heinitz S, Stinson EJ, Begaye B, Hohenadel M, Piaggi P, Krakoff J, Votruba SB. Fasting glucagon-like peptide 1 concentration is associated with lower carbohydrate intake and increases with overeating. J Endocrinol Invest 2019;42:557-66. [PMID: 30284224 DOI: 10.1007/s40618-018-0954-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
133 Yoo ER, Sallam S, Perumpail BJ, Iqbal U, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. When to Initiate Weight Loss Medications in the NAFLD Population. Diseases 2018;6:E91. [PMID: 30274326 DOI: 10.3390/diseases6040091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
134 LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018;320:1172-91. [PMID: 30326501 DOI: 10.1001/jama.2018.7777] [Cited by in Crossref: 200] [Cited by in F6Publishing: 215] [Article Influence: 50.0] [Reference Citation Analysis]
135 Mangan A, Docherty NG, Le Roux CW, Al-Najim W. Current and emerging pharmacotherapy for prediabetes: are we moving forward? Expert Opin Pharmacother 2018;19:1663-73. [PMID: 30198813 DOI: 10.1080/14656566.2018.1517155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
136 Namekawa J, Nemoto S, Sunada G, Takanashi Y, Fujio S, Shirai M, Asai F. Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist. J Vet Med Sci 2018;80:1515-23. [PMID: 30175725 DOI: 10.1292/jvms.18-0306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
137 Velapati SR, Shah M, Kuchkuntla AR, Abu-dayyeh B, Grothe K, Hurt RT, Mundi MS. Weight Regain After Bariatric Surgery: Prevalence, Etiology, and Treatment. Curr Nutr Rep 2018;7:329-34. [DOI: 10.1007/s13668-018-0243-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 15.0] [Reference Citation Analysis]
138 Yuan X, Ni H, Chen X, Feng X, Wu Q, Chen J. Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora. J Cell Biochem 2018;119:10067-74. [PMID: 30129059 DOI: 10.1002/jcb.27343] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
139 Meyer-Gerspach AC, Ly HG, Borgwardt S, Dupont P, Beglinger C, Van Oudenhove L, Wölnerhanssen BK. Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy. Diabetes Obes Metab 2018;20:2330-8. [PMID: 29790260 DOI: 10.1111/dom.13369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
140 Stirban OA. Wichtige Erkenntnisse und offene Fragen. Info Diabetol 2018;12:3-3. [DOI: 10.1007/s15034-018-1298-0] [Reference Citation Analysis]
141 Dedov II, Mel'nichenko GA, Shestakova MV, Troshina EA, Mazurina NV, Shestakova EA, Yashkov YI, Neimark AE, Biryukova EV, Bondarenko IZ, Bordan NS, Dzgoeva FH, Ershova EV, Komshilova KA, Mkrtumyan AM, Petunina NA, Romantsova TI, Starostina EG, Strongin LG, Suplotova LA, Fadeyev VV. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obes metabol 2018;15:53-70. [DOI: 10.14341/omet2018153-70] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 18.0] [Reference Citation Analysis]
142 Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. Gastroenterology 2018;154:1309-1319.e7. [PMID: 29305933 DOI: 10.1053/j.gastro.2017.12.024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
143 Madsbad S, Holst JJ. Treatment with GLP-1 Receptor Agonists. In: Bonora E, Defronzo R, editors. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Cham: Springer International Publishing; 2018. pp. 1-45. [DOI: 10.1007/978-3-319-27317-4_20-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
144 Nadolsky KZ. Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population. Mil Med 2018;183:45-50. [PMID: 29420770 DOI: 10.1093/milmed/usx074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
145 Anandhakrishnan A, Korbonits M. Glucagon-Like Peptide 1 and Human Obesity. Practical Guide to Obesity Medicine 2018. [DOI: 10.1016/b978-0-323-48559-3.00003-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Madsbad S, Holst JJ. Treatment with GLP-1 Receptor Agonists. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_20] [Reference Citation Analysis]
147 Ackermann MA. Medical Management of Obesity. Global Bariatric Surgery 2018. [DOI: 10.1007/978-3-319-93545-4_35] [Reference Citation Analysis]
148 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-jack S, Defronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, Mcgill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice 2018;24:91-121. [DOI: 10.4158/cs-2017-0153] [Cited by in Crossref: 326] [Cited by in F6Publishing: 341] [Article Influence: 81.5] [Reference Citation Analysis]
149 Shaw Tronieri J, Wadden TA, Berkowitz RI, Chao AM, Pearl RL, Alamuddin N, Leonard SM, Carvajal R, Bakizada ZM, Pinkasavage E, Gruber KA, Walsh OA, Alfaris N. A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet. Obesity (Silver Spring) 2018;26:299-309. [PMID: 29288545 DOI: 10.1002/oby.22081] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
150 Rendell MS. Albiglutide for the management of type 2 diabetes. Expert Review of Endocrinology & Metabolism 2017;13:1-8. [DOI: 10.1080/17446651.2018.1419061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
151 Yu M, Mody R, Landó LF, Shui A, Kallenbach L, Slipski L, de Oliveira CP. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes. Clinical Therapeutics 2017;39:2399-408. [DOI: 10.1016/j.clinthera.2017.11.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
152 Ferjan S, Janez A, Jensterle M. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. Metabolic Syndrome and Related Disorders 2017;15:515-20. [DOI: 10.1089/met.2017.0095] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
153 Gottlieb A, Yanover C, Cahan A, Goldschmidt Y. Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study. BMJ Open Diabetes Res Care 2017;5:e000435. [PMID: 29299328 DOI: 10.1136/bmjdrc-2017-000435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
154 Mete R, Georgousopoulou EN, Mellor DD, Khoo J, Cheong M, Leeds AR, Allan K, Avery A, Hart K, Muir A, Abdeen G, Ross NP, Bruce D, O'kane M, Hopkins M, Gibbons C, King NA, Mead BR, Boyland EJ, Avenell A, Robertson C, Archibald D, Spanos D, Melville CA, Jones N, Mccombie L, Grieve E. Weight management in adults. Advanced Nutrition and Dietetics in Obesity 2017. [DOI: 10.1002/9781118857991.ch4] [Reference Citation Analysis]
155 Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab 2018;20:734-9. [PMID: 28950422 DOI: 10.1111/dom.13125] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
156 Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab 2016;18:558-70. [PMID: 26936802 DOI: 10.1111/dom.12657] [Cited by in Crossref: 96] [Cited by in F6Publishing: 101] [Article Influence: 19.2] [Reference Citation Analysis]
157 Koot R, van Borren M, de Boer H. Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia. Eur J Case Rep Intern Med 2017;4:000712. [PMID: 30755910 DOI: 10.12890/2017_000712] [Reference Citation Analysis]
158 Hall KD, Sanghvi A, Göbel B. Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy. Obesity (Silver Spring) 2017;25:2088-91. [PMID: 29071809 DOI: 10.1002/oby.21978] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
159 Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14:12-24. [PMID: 29027993 DOI: 10.1038/nrendo.2017.122] [Cited by in Crossref: 205] [Cited by in F6Publishing: 214] [Article Influence: 41.0] [Reference Citation Analysis]
160 Himmerich H, Treasure J. Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol 2018;11:95-108. [PMID: 28933969 DOI: 10.1080/17512433.2018.1383895] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
161 Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes? Diabetes Metab Syndr Obes 2017;10:413-7. [PMID: 29042804 DOI: 10.2147/DMSO.S141571] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
162 Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol 2018;6:237-48. [PMID: 28919062 DOI: 10.1016/S2213-8587(17)30236-X] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 25.8] [Reference Citation Analysis]
163 Mazzucca AC, Parra MT, Latorraca CO, Spinola-castro AM, Riera R. Glucagon-like peptide (GLP)-1 analogues for normoglycaemic, overweight or obese adults. Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012793] [Reference Citation Analysis]
164 Gilor C, Rudinsky AJ, Hall MJ. New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs. J Feline Med Surg 2016;18:733-43. [PMID: 27562982 DOI: 10.1177/1098612X16660441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
165 Hocking S, Dear A, Cowley MA. Current and emerging pharmacotherapies for obesity in Australia. Obes Res Clin Pract 2017;11:501-21. [PMID: 28818558 DOI: 10.1016/j.orcp.2017.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
166 Rendell MS. The safety of albiglutide for the treatment of type 2 diabetes. Expert Opin Drug Saf 2017;16:1089-97. [PMID: 28678550 DOI: 10.1080/14740338.2017.1351538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
167 O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab 2017;19:1529-36. [PMID: 28386912 DOI: 10.1111/dom.12963] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
168 Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2017;74:719-28. [PMID: 28601891 DOI: 10.1001/jamapsychiatry.2017.1220] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 18.0] [Reference Citation Analysis]
169 . ▾ Liraglutide for weight management. Drug Ther Bull 2017;55:78-81. [PMID: 28701318 DOI: 10.1136/dtb.2017.7.0502] [Reference Citation Analysis]
170 Srikanth S, Deedwania P. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. Curr Hypertens Rep 2016;18:76. [PMID: 27730495 DOI: 10.1007/s11906-016-0683-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
171 Sweeting AN, Caterson ID. Approaches to obesity management: Obesity management. Intern Med J 2017;47:734-9. [DOI: 10.1111/imj.13474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
172 Brea Á, Pintó X, Ascaso JF, Blasco M, Díaz Á, González-santos P, Hernández-mijares A, Mantilla T, Millán J, Pedro-botet J. Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico. Clínica e Investigación en Arteriosclerosis 2017;29:185-200. [DOI: 10.1016/j.arteri.2016.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
173 Brea Á, Pintó X, Ascaso JF, Blasco M, Díaz Á, González-santos P, Hernández-mijares A, Mantilla T, Millán J, Pedro-botet J. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. Clínica e Investigación en Arteriosclerosis (English Edition) 2017;29:185-200. [DOI: 10.1016/j.artere.2017.07.001] [Reference Citation Analysis]
174 Shettar V, Patel S, Kidambi S. Epidemiology of Obesity and Pharmacologic Treatment Options. Nutr Clin Pract 2017;32:441-62. [DOI: 10.1177/0884533617713189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
175 Röder PV, Wong X, Hong W, Han W. Molecular regulation of insulin granule biogenesis and exocytosis. Biochem J 2016;473:2737-56. [PMID: 27621482 DOI: 10.1042/BCJ20160291] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
176 Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab 2017;19:1276-88. [PMID: 28345814 DOI: 10.1111/dom.12954] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
177 Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1-7. [PMID: 28532816 DOI: 10.1016/j.phrs.2017.05.013] [Cited by in Crossref: 249] [Cited by in F6Publishing: 202] [Article Influence: 49.8] [Reference Citation Analysis]
178 Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;5:CD012204. [PMID: 28489279 DOI: 10.1002/14651858.CD012204.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
179 von Scholten BJ, Davies MJ, Persson F, Hansen TW, Madsbad S, Endahl L, Jepsen CH, Rossing P. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. J Diabetes Complications 2017;31:1164-8. [PMID: 28462892 DOI: 10.1016/j.jdiacomp.2017.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
180 Rendell M. United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. Drug Des Devel Ther 2017;11:1209-20. [PMID: 28458515 DOI: 10.2147/DDDT.S132581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
181 Gottlieb A, Yanover C, Cahan A, Goldschmidt Y. Estimating Effects Of Second Line Therapy For Type 2 Diabetes Mellitus: Retrospective Cohort Study.. [DOI: 10.1101/130724] [Reference Citation Analysis]
182 Vari SG. Obesity: Rubensian beauty turned into major health problem. Croat Med J 2017;58:89-91. [PMID: 28409491 DOI: 10.3325/cmj.2017.58.89] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
183 le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:1399-409. [PMID: 28237263 DOI: 10.1016/S0140-6736(17)30069-7] [Cited by in Crossref: 363] [Cited by in F6Publishing: 366] [Article Influence: 72.6] [Reference Citation Analysis]
184 Farr OM, Mantzoros CS. Treating prediabetes in the obese: are GLP-1 analogues the answer? Lancet 2017;389:1371-2. [PMID: 28237265 DOI: 10.1016/S0140-6736(17)30315-X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
185 Hyde KM, Blonde GD, le Roux CW, Spector AC. Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection. Physiol Behav 2017;177:4-12. [PMID: 28366815 DOI: 10.1016/j.physbeh.2017.03.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
186 Kirk SF, Shamliyan TA, Middleton M. Glucagon-like peptide-1 agonists for weight loss in people with obesity. Obesity Medicine 2017;5:29-43. [DOI: 10.1016/j.obmed.2017.01.003] [Reference Citation Analysis]
187 Webb DL, Abrahamsson N, Sundbom M, Hellström PM. Bariatric surgery - time to replace with GLP-1? Scand J Gastroenterol 2017;52:635-40. [PMID: 28276830 DOI: 10.1080/00365521.2017.1293154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
188 Zhou QX, Wang ZY, Zhao HF, Wang S. The effects of GLP-1 analogues on pre-diabetes of the children. Exp Ther Med 2017;13:1426-30. [PMID: 28413488 DOI: 10.3892/etm.2017.4129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
189 Merlotti C, Ceriani V, Morabito A, Pontiroli AE. Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis. Int J Obes 2017;41:672-82. [DOI: 10.1038/ijo.2017.31] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
190 Jensterle M, Kravos NA, Goričar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 2017;17:5. [PMID: 28143456 DOI: 10.1186/s12902-017-0155-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
191 Boles A, Kandimalla R, Reddy PH. Dynamics of diabetes and obesity: Epidemiological perspective. Biochim Biophys Acta Mol Basis Dis. 2017;1863:1026-1036. [PMID: 28130199 DOI: 10.1016/j.bbadis.2017.01.016] [Cited by in Crossref: 115] [Cited by in F6Publishing: 89] [Article Influence: 23.0] [Reference Citation Analysis]
192 Wei W, Buysman E, Grabner M, Xie L, Brekke L, Ke X, Chu JW, Levin PA. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies. Diabetes Obes Metab 2017;19:375-86. [PMID: 27860158 DOI: 10.1111/dom.12828] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
193 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocr Pract. 2017;23:207-238. [PMID: 28095040 DOI: 10.4158/ep161682.cs] [Cited by in Crossref: 312] [Cited by in F6Publishing: 330] [Article Influence: 62.4] [Reference Citation Analysis]
194 Farr OM, Mantzoros CS. Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. Metabolism 2017;70:192-5. [PMID: 28095990 DOI: 10.1016/j.metabol.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
195 Palmer KD, Apovian CM. Obesity. Nutrition in the Prevention and Treatment of Disease 2017. [DOI: 10.1016/b978-0-12-802928-2.00022-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
196 Guglielmi V, Sbraccia P. GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. Eat Weight Disord 2017;22:231-40. [DOI: 10.1007/s40519-016-0352-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
197 Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3:3-14. [PMID: 28392927 DOI: 10.1002/osp4.84] [Cited by in Crossref: 106] [Cited by in F6Publishing: 116] [Article Influence: 17.7] [Reference Citation Analysis]
198 Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 [PMID: 28031776 DOI: 10.4239/wjd.v7.i20.572] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
199 Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, Genovese S, Ceriello A. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol 2016;15:162. [PMID: 27912784 DOI: 10.1186/s12933-016-0480-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 12.8] [Reference Citation Analysis]
200 Álvarez J, Escribano P, Trifu D. Tratamiento de la obesidad. Medicine - Programa de Formación Médica Continuada Acreditado 2016;12:1324-1336. [DOI: 10.1016/j.med.2016.12.002] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Garvey WT. Individualizing Lifestyle Therapy for Patients with Obesity. Endocrine Practice 2016;22:14-20. [DOI: 10.1016/s1530-891x(20)43231-8] [Reference Citation Analysis]
202 Kajiwara M, Tanaka A, Kawasaki T, Nakao K, Sakamoto T, Toyoda S, Inoue T, Koga N, Node K. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. J Cardiol 2017;69:511-7. [PMID: 27894787 DOI: 10.1016/j.jjcc.2016.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
203 Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:162-71. [PMID: 27717222 DOI: 10.1111/dom.12795] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
204 O'neil PM, Garvey WT, Gonzalez-campoy JM, Mora P, Ortiz RV, Guerrero G, Claudius B, Pi-sunyer X. Effects of Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hipanic Populations: Subgroup Analysis from Scale Randomized Trials. Endocrine Practice 2016;22:1277-87. [DOI: 10.4158/ep151181.or] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
205 Rankin W, Wittert G. Anti-obesity drugs. Curr Opin Lipidol. 2015;26:536-543. [PMID: 26382553 DOI: 10.1097/mol.0000000000000232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
206 Rendell MS. Albiglutide: a unique GLP-1 receptor agonist. Expert Opin Biol Ther 2016;16:1557-69. [PMID: 27677385 DOI: 10.1080/14712598.2016.1240780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
207 Isaacs D, Prasad-reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. American Journal of Health-System Pharmacy 2016;73:1493-507. [DOI: 10.2146/ajhp150990] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
208 Burcelin R, Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity: GLP-1 receptor agonists in overweight and obesity. Obesity Reviews 2017;18:86-98. [DOI: 10.1111/obr.12465] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
209 Chang X, Wang Z, Zhang J, Yan H, Bian H, Xia M, Lin H, Jiang J, Gao X. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med. 2016;14:266. [PMID: 27629750 DOI: 10.1186/s12967-016-0982-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 8.5] [Reference Citation Analysis]
210 Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs 2016;25:1167-79. [PMID: 27563838 DOI: 10.1080/13543784.2016.1221925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
211 Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016. Br Med Bull 2016;119:143-56. [PMID: 27543499 DOI: 10.1093/bmb/ldw031] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
212 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary. Endocr Pract. 2016;22:84-113. [PMID: 26731084 DOI: 10.4158/ep151126.cs] [Cited by in Crossref: 310] [Cited by in F6Publishing: 348] [Article Influence: 51.7] [Reference Citation Analysis]
213 Vorsanger MH, Subramanyam P, Weintraub HS, Lamm SH, Underberg JA, Gianos E, Goldberg IJ, Schwartzbard AZ. Cardiovascular Effects of the New Weight Loss Agents. Journal of the American College of Cardiology 2016;68:849-59. [DOI: 10.1016/j.jacc.2016.06.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
214 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE)., American College of Endocrinology (ACE). CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract 2015;21:1403-14. [PMID: 26642101 DOI: 10.4158/EP151063.CS] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
215 Van Gaal L, Dirinck E. Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. Diabetes Care 2016;39 Suppl 2:S260-7. [PMID: 27440841 DOI: 10.2337/dcS15-3016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
216 Neeland IJ, Grundy SM, Li X, Adams-Huet B, Vega GL. Comparison of visceral fat mass measurement by dual-X-ray absorptiometry and magnetic resonance imaging in a multiethnic cohort: the Dallas Heart Study. Nutr Diabetes 2016;6:e221. [PMID: 27428873 DOI: 10.1038/nutd.2016.28] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 12.8] [Reference Citation Analysis]
217 Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines Formedical Care of Patients with Obesity. Endocrine Practice 2016;22:1-203. [DOI: 10.4158/ep161365.gl] [Cited by in Crossref: 601] [Cited by in F6Publishing: 645] [Article Influence: 100.2] [Reference Citation Analysis]
218 Levine JA, Kaihara KA, Layden BT, Wicksteed B. Long-term activation of PKA in β-cells provides sustained improvement to glucose control, insulin sensitivity and body weight. Islets 2016;8:125-34. [PMID: 27340937 DOI: 10.1080/19382014.2016.1198457] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
219 Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016;315:2424-34. [PMID: 27299618 DOI: 10.1001/jama.2016.7602] [Cited by in Crossref: 397] [Cited by in F6Publishing: 448] [Article Influence: 66.2] [Reference Citation Analysis]
220 Kusminski CM, Bickel PE, Scherer PE. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov 2016;15:639-60. [PMID: 27256476 DOI: 10.1038/nrd.2016.75] [Cited by in Crossref: 405] [Cited by in F6Publishing: 416] [Article Influence: 67.5] [Reference Citation Analysis]
221 Yang Y, Chen F, Wan D, Liu Y, Yang L, Feng H, Cui X, Gao X, Song H. Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc. PLoS One 2016;11:e0156449. [PMID: 27232339 DOI: 10.1371/journal.pone.0156449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
222 Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes 2016;6:233-42. [PMID: 27198973 DOI: 10.1111/cob.12146] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
223 Tek C. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. Patient Prefer Adherence 2016;10:751-9. [PMID: 27217728 DOI: 10.2147/PPA.S84778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
224 Hoelmkjaer KM, Wewer Albrechtsen NJ, Holst JJ, Cronin AM, Nielsen DH, Mandrup-Poulsen T, Bjornvad CR. A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. PLoS One 2016;11:e0154727. [PMID: 27136422 DOI: 10.1371/journal.pone.0154727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
225 López-lópez J, Di Stefano KA, Velásquez E, Camacho PA, López-jaramillo P. ¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica? Revista Colombiana de Cardiología 2016;23:200-9. [DOI: 10.1016/j.rccar.2015.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
226 Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016;40:1310-9. [PMID: 27005405 DOI: 10.1038/ijo.2016.52] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 28.2] [Reference Citation Analysis]
227 Tonstad S, Rössner S, Rissanen A, Astrup A. Medical management of obesity in Scandinavia 2016. Obesity Medicine 2016;1:38-44. [DOI: 10.1016/j.obmed.2016.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
228 Apovian CM. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future Cardiology 2016;12:129-38. [DOI: 10.2217/fca.15.79] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
229 Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, Hu FB, Raz I, Van Gaal L, Wolfe BM, Ryan DH. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2015;38:1567-82. [PMID: 26421334 DOI: 10.2337/dc15-1081] [Cited by in Crossref: 134] [Cited by in F6Publishing: 145] [Article Influence: 22.3] [Reference Citation Analysis]
230 Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75:899-910. [PMID: 25985864 DOI: 10.1007/s40265-015-0408-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
231 Ard J, Cannon A, Lewis CE, Lofton H, Vang Skjøth T, Stevenin B, Pi-Sunyer X. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes Obes Metab 2016;18:430-5. [PMID: 26744025 DOI: 10.1111/dom.12632] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
232 Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet 2016;387:1947-56. [PMID: 26868660 DOI: 10.1016/S0140-6736(16)00271-3] [Cited by in Crossref: 497] [Cited by in F6Publishing: 517] [Article Influence: 82.8] [Reference Citation Analysis]
233 Mayfield K, Siskind D, Winckel K, Russell AW, Kisely S, Smith G, Hollingworth S. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol 2016;30:227-36. [PMID: 26801056 DOI: 10.1177/0269881115625496] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
234 Zhang L, Zhang M, Zhang Y, Tong N. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep 2016;6:18904. [PMID: 26742577 DOI: 10.1038/srep18904] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
235 Nisoli E, Muratori F. Pharmacological Management. Clinical Management of Overweight and Obesity 2016. [DOI: 10.1007/978-3-319-24532-4_5] [Reference Citation Analysis]
236 Gallwitz B. Glucagon-like peptide-1 receptor agonists. Handbook of Incretin-based Therapies in Type 2 Diabetes 2016. [DOI: 10.1007/978-3-319-08982-9_3] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
237 Blackstone RP. Beyond Traditional Management: The Use of Medications in the Treatment of Obesity. Obesity 2016. [DOI: 10.1007/978-3-319-39409-1_10] [Reference Citation Analysis]
238 Engeli S. Medikamentöse Behandlung der Adipositas. PSYCH up2date 2016;10:47-64. [DOI: 10.1055/s-0041-106154] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
239 Traish AM, Trussler JT. Effects of Lifestyle Changes and Testosterone Therapy on Erectile Function. Contemporary Treatment of Erectile Dysfunction 2016. [DOI: 10.1007/978-3-319-31587-4_8] [Reference Citation Analysis]
240 Cui X, Meng Q, Chu Y, Gu X, Tang Y, Zhou F, Fei Y, Fu J, Han J. Glucagon-like peptide-1 loaded phospholipid micelles for the treatment of type 2 diabetes: improved pharmacokinetic behaviours and prolonged glucose-lowering effects. RSC Adv 2016;6:94408-16. [DOI: 10.1039/c6ra22648e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
241 Montanya E. Future and emerging therapies. Handbook of Incretin-based Therapies in Type 2 Diabetes 2016. [DOI: 10.1007/978-3-319-08982-9_6] [Reference Citation Analysis]
242 Apovian CM, Garvey WT, Ryan DH. Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity (Silver Spring) 2015;23 Suppl 2:S1-S26. [PMID: 26154880 DOI: 10.1002/oby.21140] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
243 Shihab HM, Akande T, Armstrong K, Singh S, Loke YK. Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials. World J Meta-Anal 2015; 3(6): 254-283 [DOI: 10.13105/wjma.v3.i6.254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
244 Jorsal T, Rungby J, Knop FK, Vilsbøll T. GLP-1 and Amylin in the Treatment of Obesity. Curr Diab Rep 2016;16. [DOI: 10.1007/s11892-015-0693-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
245 Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts 2015;8:402-24. [PMID: 26641646 DOI: 10.1159/000442721] [Cited by in Crossref: 565] [Cited by in F6Publishing: 604] [Article Influence: 80.7] [Reference Citation Analysis]
246 Sweeting AN, Hocking SL, Markovic TP. Pharmacotherapy for the treatment of obesity. Molecular and Cellular Endocrinology 2015;418:173-83. [DOI: 10.1016/j.mce.2015.09.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
247 Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord 2015;16:249-68. [DOI: 10.1007/s11154-015-9323-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 5.1] [Reference Citation Analysis]
248 Kooijman S, van den Heuvel JK, Rensen PC. Neuronal Control of Brown Fat Activity. Trends in Endocrinology & Metabolism 2015;26:657-68. [DOI: 10.1016/j.tem.2015.09.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
249 Wharton S. Current Perspectives on Long-term Obesity Pharmacotherapy. Can J Diabetes 2016;40:184-91. [PMID: 26507402 DOI: 10.1016/j.jcjd.2015.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
250 Apovian CM, Aronne LJ. The 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults: What Is New About Diet, Drugs, and Surgery for Obesity? Circulation 2015;132:1586-91. [DOI: 10.1161/circulationaha.114.010772] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
251 Grunddal KV, Ratner CF, Svendsen B, Sommer F, Engelstoft MS, Madsen AN, Pedersen J, Nøhr MK, Egerod KL, Nawrocki AR, Kowalski T, Howard AD, Poulsen SS, Offermanns S, Bäckhed F, Holst JJ, Holst B, Schwartz TW. Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism. Endocrinology 2016;157:176-94. [PMID: 26469136 DOI: 10.1210/en.2015-1600] [Cited by in Crossref: 102] [Cited by in F6Publishing: 103] [Article Influence: 14.6] [Reference Citation Analysis]
252 Liu L, Segura A, Hagemann AR. Obesity Education Strategies for Cancer Prevention in Women's Health. Curr Obstet Gynecol Rep 2015;4:249-58. [PMID: 26877893 DOI: 10.1007/s13669-015-0129-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
253 Butsch WS. Obesity medications: what does the future look like? Current Opinion in Endocrinology & Diabetes and Obesity 2015;22:360-6. [DOI: 10.1097/med.0000000000000192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
254 Scott LJ. Liraglutide in obesity: a guide to its use in the EU. Drugs Ther Perspect 2015;31:334-340. [DOI: 10.1007/s40267-015-0241-x] [Reference Citation Analysis]
255 Ghuman NK, Saadah LM, Al Najjar MS, Shaheen DY, Am SI, Al Ali MM. Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients. Clin Med Insights Endocrinol Diabetes 2015;8:67-72. [PMID: 26441485 DOI: 10.4137/CMED.S31756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
256 Lunati ME, Grancini V, Colombo C, Palmieri E, Resi V, Perrino M, Orsi E, Fugazzola L. Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment. Metabolism 2016;65:1-6. [PMID: 26683791 DOI: 10.1016/j.metabol.2015.09.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
257 Fierabracci P. Studio randomizzato, controllato sugli effetti della Liraglutide alla dose di 3 mg nel trattamento dell’eccesso ponderale. L'Endocrinologo 2015;16:183-183. [DOI: 10.1007/s40619-015-0136-z] [Reference Citation Analysis]
258 Shan PF, Ji XL, Wang L, Li P, Ren YZ. Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346. Diabetes Care 2015;38:e148-9. [PMID: 26294784 DOI: 10.2337/dc15-0887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
259 Siegmund T. Hochdosiertes GLP-1-Analogon zur Gewichtskontrolle erfolgreich. Info Diabetol 2015;9:27-28. [DOI: 10.1007/s15034-015-0632-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
260 Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, Zeng MS, Tu YF, Feng R, Jia WP, Liu J, Deng W, Jiang JD, Gao X. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015;10:e0134172. [PMID: 26252777 DOI: 10.1371/journal.pone.0134172] [Cited by in Crossref: 108] [Cited by in F6Publishing: 122] [Article Influence: 15.4] [Reference Citation Analysis]
261 Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation. 2015;132:691-718. [PMID: 26246173 DOI: 10.1161/cir.0000000000000230] [Cited by in Crossref: 249] [Cited by in F6Publishing: 261] [Article Influence: 35.6] [Reference Citation Analysis]
262 Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health., Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research., American Diabetes Association. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care 2015;38:1777-803. [PMID: 26246459 DOI: 10.2337/dci15-0012] [Cited by in Crossref: 274] [Cited by in F6Publishing: 295] [Article Influence: 39.1] [Reference Citation Analysis]
263 Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond) 2016;40:162-70. [PMID: 26219417 DOI: 10.1038/ijo.2015.139] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 12.9] [Reference Citation Analysis]
264 Defronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.19] [Cited by in Crossref: 746] [Cited by in F6Publishing: 788] [Article Influence: 106.6] [Reference Citation Analysis]
265 Rizvi AA, Patti AM, Giglio RV, Nikolic D, Amato A, Al-Busaidi N, Al-Rasadi K, Soresi M, Banach M, Montalto G, Rizzo M. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther 2015;15:1391-7. [PMID: 26195184 DOI: 10.1517/14712598.2015.1067299] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
266 Busetto L, Dixon J, De Luca M, Shikora S, Pories W, Angrisani L. Bariatric surgery in class I obesity: a Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg. 2014;24:487-519. [PMID: 24638958 DOI: 10.1007/s11695-014-1214-1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 79] [Article Influence: 10.0] [Reference Citation Analysis]
267 Fujioka K, Sparre T, Sun LY, Krogsgaard S, Kushner RF. Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience. J Diabetes Sci Technol 2015;10:164-74. [PMID: 26183599 DOI: 10.1177/1932296815593295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
268 Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17:1021-1032. [PMID: 26040215 DOI: 10.1111/dom.12502] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
269 Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab 2015;6:109-34. [PMID: 26137215 DOI: 10.1177/2042018815580257] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
270 Lechleitner M. The elderly as a target for obesity treatment. Expert Rev Endocrinol Metab 2015;10:375-80. [PMID: 30293491 DOI: 10.1586/17446651.2015.1028530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
271 Aroda VR, Getaneh A. Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Rev Endocrinol Metab 2015;10:381-98. [PMID: 30293496 DOI: 10.1586/17446651.2015.1054280] [Reference Citation Analysis]
272 Min T, Stephens JW. Targeting abdominal obesity in diabetes. Diabetes Management 2015;5:301-309. [DOI: 10.2217/dmt.15.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
273 Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI, Santos MS, Oliveira CR, Moreira PI, Duarte AI. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J Diabetes 2015; 6(6): 807-827 [PMID: 26131323 DOI: 10.4239/wjd.v6.i6.807] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
274 Iepsen EW, Torekov SS, Holst JJ. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Review of Cardiovascular Therapy 2015;13:753-67. [DOI: 10.1586/14779072.2015.1054810] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
275 Behary P, Cegla J, Tan TM, Bloom SR. Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones. Postgraduate Medicine 2015;127:494-502. [DOI: 10.1080/00325481.2015.1048181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
276 Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 2015;8:32. [PMID: 26032655 DOI: 10.1186/s13048-015-0161-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
277 Howland RH. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. J Psychosoc Nurs Ment Health Serv 2015;53:19-22. [DOI: 10.3928/02793695-20150526-02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
278 Garber AJ. Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Prediabetes to Type 2 Diabetes. Endocrine Practice 2015;21:634-44. [DOI: 10.4158/ep14460.ra] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
279 de Mello AH, Prá M, Cardoso LC, de Bona Schraiber R, Rezin GT. Incretin-based therapies for obesity treatment. Metabolism 2015;64:967-81. [PMID: 26072135 DOI: 10.1016/j.metabol.2015.05.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
280 Jensterle M, Pirš B, Goričar K, Dolžan V, Janež A. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol 2015;71:817-24. [PMID: 25991051 DOI: 10.1007/s00228-015-1868-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
281 Behary P, Miras AD. Food preferences and underlying mechanisms after bariatric surgery. Proc Nutr Soc 2015;74:419-25. [PMID: 25990312 DOI: 10.1017/S0029665115002074] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 7.7] [Reference Citation Analysis]
282 Martin KA, Mani MV, Mani A. New targets to treat obesity and the metabolic syndrome. Eur J Pharmacol 2015;763:64-74. [PMID: 26001373 DOI: 10.1016/j.ejphar.2015.03.093] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 11.3] [Reference Citation Analysis]
283 Clements JN, Shealy KM. Liraglutide: an injectable option for the management of obesity. Ann Pharmacother 2015;49:938-44. [PMID: 25986009 DOI: 10.1177/1060028015586806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
284 Traish AM. Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes 2014;21:313-22. [PMID: 25105998 DOI: 10.1097/MED.0000000000000086] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
285 Hainer V, Aldhoon-Hainerová I. Tolerability and safety of the new anti-obesity medications. Drug Saf. 2014;37:693-702. [PMID: 25096956 DOI: 10.1007/s40264-014-0206-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
286 Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015;23:1119-1129. [PMID: 25959380 DOI: 10.1002/oby.21107] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
287 Miglioranza Scavuzzi B, Miglioranza LH, Henrique FC, Pitelli Paroschi T, Lozovoy MA, Simão AN, Dichi I. The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks. Expert Opin Ther Targets 2015;19:1127-38. [PMID: 25872805 DOI: 10.1517/14728222.2015.1028361] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
288 von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications 2015;29:670-4. [PMID: 25935863 DOI: 10.1016/j.jdiacomp.2015.04.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
289 Gallwitz B. GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015. Eur Endocrinol 2015;11:21-5. [PMID: 29632562 DOI: 10.17925/EE.2015.11.01.21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
290 Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, Leroith D, Levy P, Mcgill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015. Endocrine Practice 2015;21:1-87. [DOI: 10.4158/ep15672.glsuppl] [Cited by in Crossref: 405] [Cited by in F6Publishing: 410] [Article Influence: 57.9] [Reference Citation Analysis]
291 Mordes JP, Liu C, Xu S. Medications for weight loss: . Current Opinion in Endocrinology & Diabetes and Obesity 2015;22:91-7. [DOI: 10.1097/med.0000000000000140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
292 Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther 2015;9:1867-75. [PMID: 25848222 DOI: 10.2147/DDDT.S58459] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 8.6] [Reference Citation Analysis]
293 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 243] [Cited by in F6Publishing: 258] [Article Influence: 34.7] [Reference Citation Analysis]
294 Abdul-ghani M, Defronzo RA, Eldor R. Combination therapy in type 2 diabetes mellitus. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch46] [Reference Citation Analysis]
295 Astrup A. Treatment of obesity: lifestyle and pharmacotherapy. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch33] [Reference Citation Analysis]
296 Schumacher D. Pharmacological Management of the Obese Patient. American Journal of Lifestyle Medicine 2015;9:137-156. [DOI: 10.1177/1559827613504733] [Reference Citation Analysis]
297 Lau DC. Recommendations for obesity management and prevention have come a long way. Can J Diabetes 2015;39:89-90. [PMID: 25702861 DOI: 10.1016/j.jcjd.2015.01.289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, Kopelman P. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet. 2015;385:2521-2533. [PMID: 25703112 DOI: 10.1016/s0140-6736(14)61748-7] [Cited by in Crossref: 241] [Cited by in F6Publishing: 258] [Article Influence: 34.4] [Reference Citation Analysis]
299 Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud 2014;11:202-30. [PMID: 26177483 DOI: 10.1900/RDS.2014.11.202] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 19.4] [Reference Citation Analysis]
300 Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:12. [PMID: 25645567 DOI: 10.1186/s12933-014-0171-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
301 Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, Dauriz M, Hivert MF, Raghavan S, Lipovich L, Hidalgo B, Fox K, Huffman JE, An P, Lu Y, Rasmussen-Torvik LJ, Grarup N, Ehm MG, Li L, Baldridge AS, Stančáková A, Abrol R, Besse C, Boland A, Bork-Jensen J, Fornage M, Freitag DF, Garcia ME, Guo X, Hara K, Isaacs A, Jakobsdottir J, Lange LA, Layton JC, Li M, Hua Zhao J, Meidtner K, Morrison AC, Nalls MA, Peters MJ, Sabater-Lleal M, Schurmann C, Silveira A, Smith AV, Southam L, Stoiber MH, Strawbridge RJ, Taylor KD, Varga TV, Allin KH, Amin N, Aponte JL, Aung T, Barbieri C, Bihlmeyer NA, Boehnke M, Bombieri C, Bowden DW, Burns SM, Chen Y, Chen YD, Cheng CY, Correa A, Czajkowski J, Dehghan A, Ehret GB, Eiriksdottir G, Escher SA, Farmaki AE, Frånberg M, Gambaro G, Giulianini F, Goddard WA 3rd, Goel A, Gottesman O, Grove ML, Gustafsson S, Hai Y, Hallmans G, Heo J, Hoffmann P, Ikram MK, Jensen RA, Jørgensen ME, Jørgensen T, Karaleftheri M, Khor CC, Kirkpatrick A, Kraja AT, Kuusisto J, Lange EM, Lee IT, Lee WJ, Leong A, Liao J, Liu C, Liu Y, Lindgren CM, Linneberg A, Malerba G, Mamakou V, Marouli E, Maruthur NM, Matchan A, McKean-Cowdin R, McLeod O, Metcalf GA, Mohlke KL, Muzny DM, Ntalla I, Palmer ND, Pasko D, Peter A, Rayner NW, Renström F, Rice K, Sala CF, Sennblad B, Serafetinidis I, Smith JA, Soranzo N, Speliotes EK, Stahl EA, Stirrups K, Tentolouris N, Thanopoulou A, Torres M, Traglia M, Tsafantakis E, Javad S, Yanek LR, Zengini E, Becker DM, Bis JC, Brown JB, Cupples LA, Hansen T, Ingelsson E, Karter AJ, Lorenzo C, Mathias RA, Norris JM, Peloso GM, Sheu WH, Toniolo D, Vaidya D, Varma R, Wagenknecht LE, Boeing H, Bottinger EP, Dedoussis G, Deloukas P, Ferrannini E, Franco OH, Franks PW, Gibbs RA, Gudnason V, Hamsten A, Harris TB, Hattersley AT, Hayward C, Hofman A, Jansson JH, Langenberg C, Launer LJ, Levy D, Oostra BA, O'Donnell CJ, O'Rahilly S, Padmanabhan S, Pankow JS, Polasek O, Province MA, Rich SS, Ridker PM, Rudan I, Schulze MB, Smith BH, Uitterlinden AG, Walker M, Watkins H, Wong TY, Zeggini E, Laakso M, Borecki IB, Chasman DI, Pedersen O, Psaty BM, Tai ES, van Duijn CM, Wareham NJ, Waterworth DM, Boerwinkle E, Kao WH, Florez JC, Loos RJ, Wilson JG, Frayling TM, Siscovick DS, Dupuis J, Rotter JI, Meigs JB, Scott RA, Goodarzi MO; EPIC-InterAct Consortium. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun 2015;6:5897. [PMID: 25631608 DOI: 10.1038/ncomms6897] [Cited by in Crossref: 153] [Cited by in F6Publishing: 153] [Article Influence: 21.9] [Reference Citation Analysis]
302 Kahn R, Davidson MB. The reality of type 2 diabetes prevention. Diabetes Care 2014;37:943-9. [PMID: 24652724 DOI: 10.2337/dc13-1954] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 9.1] [Reference Citation Analysis]
303 Cantini G, Di Franco A, Samavat J, Forti G, Mannucci E, Luconi M. Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol Cell Endocrinol 2015;402:43-50. [PMID: 25575456 DOI: 10.1016/j.mce.2014.12.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
304 Roh E, Kim MS. New and emerging drugs for the treatment of obesity. J Korean Med Assoc 2015;58:452. [DOI: 10.5124/jkma.2015.58.5.452] [Reference Citation Analysis]
305 Kim CS. Recent Advances for Anti-Obesity Agents. J Korean Diabetes 2015;16:260. [DOI: 10.4093/jkd.2015.16.4.260] [Reference Citation Analysis]
306 Preiato VL, Serban ED, Pasquali R, Pagotto U. Prescription Medications for the Treatment of Obesity. Multidisciplinary Approach to Obesity 2015. [DOI: 10.1007/978-3-319-09045-0_23] [Reference Citation Analysis]
307 Zhou B, Ji K, Peng A, Yang X, Huang K. GLP-1(28-36)amide, a Long Ignored Peptide Revisited. Open Biochem J 2014;8:107-11. [PMID: 25598850 DOI: 10.2174/1874091X01408010107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
308 Grunberger G, Garber AJ, Mechanick JI. Obesity management: applying clinical trial data to clinical care. Endocr Pract 2014;20 Suppl 2:6-19. [PMID: 25526732 DOI: 10.4158/EP14490.RA] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
309 Halpern B, Halpern A. Why are anti-obesity drugs stigmatized? Expert Opinion on Drug Safety 2014;14:185-9. [DOI: 10.1517/14740338.2015.995088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
310 Seimon RV, Espinoza D, Finer N, James WPT, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-pedersen C, Gebski V, Caterson ID. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. Int J Obes 2015;39:849-57. [DOI: 10.1038/ijo.2014.211] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
311 Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 2014; 5(6): 817-834 [PMID: 25512784 DOI: 10.4239/wjd.v5.i6.817] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
312 Tate M, Chong A, Robinson E, Green BD, Grieve DJ. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 2015;172:721-36. [PMID: 25231355 DOI: 10.1111/bph.12943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
313 Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev 2014;10:2-42. [PMID: 24524730 DOI: 10.2174/1573399810666140214093600] [Cited by in Crossref: 137] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
314 Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol 2015;31:142-52. [PMID: 25661549 DOI: 10.1016/j.cjca.2014.11.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
315 Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. The Lancet Diabetes & Endocrinology 2014;2:911-22. [DOI: 10.1016/s2213-8587(14)70004-x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 132] [Article Influence: 15.1] [Reference Citation Analysis]
316 Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol 2014; 20(40): 14821-14830 [PMID: 25356042 DOI: 10.3748/wjg.v20.i40.14821] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
317 Schmidt SL, Bryman D, Greenway FL, Hendricks EJ. How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals. OBES SURG 2015;25:186-90. [DOI: 10.1007/s11695-014-1466-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
318 Hanna A, Connelly KA, Josse RG, Mcintyre RS. The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. Expert Review of Endocrinology & Metabolism 2014;10:101-14. [DOI: 10.1586/17446651.2015.972370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
319 Tomkin GH. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World J Diabetes 2014; 5(5): 636-650 [PMID: 25317241 DOI: 10.4239/wjd.v5.i5.636] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
320 Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother 2014;15:2487-500. [PMID: 25260877 DOI: 10.1517/14656566.2014.965678] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
321 O'Connor-Semmes RL, Lin J, Hodge RJ, Andrews S, Chism J, Choudhury A, Nunez DJ. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clin Pharmacol Ther 2014;96:704-12. [PMID: 25238251 DOI: 10.1038/clpt.2014.187] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
322 Docherty NG, Le Roux CW. Endogenous Glucagon-Like Peptide-1 as a Potential Mediator of the Resolution of Diabetic Kidney Disease following Roux en Y Gastric Bypass: Evidence and Perspectives. Advances in Endocrinology 2014;2014:1-11. [DOI: 10.1155/2014/503846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
323 Scott RV, Tan TM, Bloom SR. Can Bayliss and Starling gut hormones cure a worldwide pandemic? J Physiol 2014;592:5153-67. [PMID: 25217372 DOI: 10.1113/jphysiol.2014.272955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
324 Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, Tong N. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials-1/:meta. J Diabetes. 2015;7:329-339. [PMID: 25043423 DOI: 10.1111/1753-0407.12198] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
325 Schwartz S. Evidence-based practice use of incretin-based therapy in the natural history of diabetes. Postgrad Med 2014;126:66-84. [PMID: 24918793 DOI: 10.3810/pgm.2014.05.2757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
326 Del Prato S. Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one? Lancet Diabetes Endocrinol 2014;2:856-8. [PMID: 25190524 DOI: 10.1016/S2213-8587(14)70185-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
327 Hoelmkjaer KM, Bjornvad CR. Management of obesity in cats. Vet Med (Auckl) 2014;5:97-107. [PMID: 32670850 DOI: 10.2147/VMRR.S40869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
328 Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne) 2014;5:140. [PMID: 25221543 DOI: 10.3389/fendo.2014.00140] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
329 Daniele G, Abdul-Ghani M, DeFronzo RA. What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 2014;15:2003-18. [PMID: 25139488 DOI: 10.1517/14656566.2014.944160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
330 Joshi S, Tough IR, Cox HM. Endogenous PYY and GLP-1 mediate l-glutamine responses in intestinal mucosa. Br J Pharmacol 2013;170:1092-101. [PMID: 23992397 DOI: 10.1111/bph.12352] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
331 Hainer V. Overview of new antiobesity drugs. Expert Opinion on Pharmacotherapy 2014;15:1975-8. [DOI: 10.1517/14656566.2014.946904] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
332 Stranges P, Khanderia U. Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf 2012;3:185-201. [PMID: 25083236 DOI: 10.1177/2042098612454290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
333 Ottney A. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. Am J Health Syst Pharm. 2013;70:2097-2103. [PMID: 24249759 DOI: 10.2146/ajhp130081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
334 Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114:1788-803. [PMID: 24855202 DOI: 10.1161/CIRCRESAHA.114.301958] [Cited by in Crossref: 253] [Cited by in F6Publishing: 264] [Article Influence: 31.6] [Reference Citation Analysis]
335 Göbel B, Sanghvi A, Hall KD. Quantifying energy intake changes during obesity pharmacotherapy. Obesity (Silver Spring) 2014;22:2105-8. [PMID: 24961931 DOI: 10.1002/oby.20813] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
336 Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014;5:135-48. [PMID: 24790728 DOI: 10.1177/2040622314522848] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 8.5] [Reference Citation Analysis]
337 Yang Y, Moghadam AA, Cordner ZA, Liang NC, Moran TH. Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers. Endocrinology 2014;155:3473-83. [PMID: 24949661 DOI: 10.1210/en.2014-1052] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
338 Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract 2013;19:864-74. [PMID: 24014010 DOI: 10.4158/EP13263.RA] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
339 Ng SY, Wilding JP. Liraglutide in the treatment of obesity. Expert Opin Biol Ther 2014;14:1215-24. [PMID: 24905058 DOI: 10.1517/14712598.2014.925870] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
340 Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. Journal of Diabetes and its Complications 2014;28:393-8. [DOI: 10.1016/j.jdiacomp.2013.12.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
341 Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, Holst JJ, Astrup A, Sjödin A. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab 2014;306:E1248-56. [PMID: 24735885 DOI: 10.1152/ajpendo.00569.2013] [Cited by in Crossref: 97] [Cited by in F6Publishing: 101] [Article Influence: 12.1] [Reference Citation Analysis]
342 DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S127-S138. [PMID: 23882037 DOI: 10.2337/dcs13-2011] [Cited by in Crossref: 171] [Cited by in F6Publishing: 187] [Article Influence: 21.4] [Reference Citation Analysis]
343 Kumar A. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. Expert Opin Biol Ther 2014;14:869-78. [PMID: 24702171 DOI: 10.1517/14712598.2014.904851] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
344 Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014;10:173-88. [PMID: 24672242 DOI: 10.2147/TCRM.S39564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
345 Charakida M, Tousoulis D, Finer N. Drug treatment of obesity in the cardiovascular patient. Curr Opin Cardiol. 2013;28:584-591. [PMID: 23928924 DOI: 10.1097/hco.0b013e3283642a4c] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
346 Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014;2014:683515. [PMID: 24738000 DOI: 10.1155/2014/683515] [Cited by in Crossref: 67] [Cited by in F6Publishing: 80] [Article Influence: 8.4] [Reference Citation Analysis]
347 Angeli FS, Shannon RP. Incretin-based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol 2014;221:T17-30. [PMID: 23926280 DOI: 10.1530/JOE-13-0195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
348 van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221:T1-16. [PMID: 24323912 DOI: 10.1530/joe-13-0414] [Cited by in Crossref: 142] [Cited by in F6Publishing: 148] [Article Influence: 17.8] [Reference Citation Analysis]
349 Gallwitz B. Extra-pancreatic effects of incretin-based therapies. Endocrine 2014;47:360-71. [PMID: 24604239 DOI: 10.1007/s12020-014-0223-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
350 Brandl EJ, Tiwari AK, Chowdhury NI, Zai CC, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics 2014;15:423-31. [DOI: 10.2217/pgs.13.247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
351 Chatzigeorgiou A, Kandaraki E, Papavassiliou AG, Koutsilieris M. Peripheral targets in obesity treatment: a comprehensive update. Obes Rev. 2014;15:487-503. [PMID: 24612276 DOI: 10.1111/obr.12163] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
352 Gadde KM. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. Expert Opin Pharmacother 2014;15:809-22. [PMID: 24548209 DOI: 10.1517/14656566.2014.890590] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
353 Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014;68:682-91. [PMID: 24548654 DOI: 10.1111/ijcp.12384] [Cited by in Crossref: 142] [Cited by in F6Publishing: 148] [Article Influence: 17.8] [Reference Citation Analysis]
354 Zhou B, Peng A, Gong H, Huang K. GLP-1R agonists therapy for type 2 diabetes. Wuhan Univ J Nat Sci 2014;19:27-33. [DOI: 10.1007/s11859-014-0974-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
355 Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014;16:673-688. [PMID: 24373150 DOI: 10.1111/dom.12251] [Cited by in Crossref: 71] [Cited by in F6Publishing: 78] [Article Influence: 8.9] [Reference Citation Analysis]
356 Kelly AS. The role of glucagon-like peptide-1 receptor agonists for the treatment of adolescent obesity. Expert Rev Endocrinol Metab 2013;8:315-7. [PMID: 30736144 DOI: 10.1586/17446651.2013.811913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
357 Ishøy PL, Knop FK, Broberg BV, Baandrup L, Fagerlund B, Jørgensen NR, Andersen UB, Rostrup E, Glenthøj BY, Ebdrup BH. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open 2014;4:e004158. [PMID: 24401727 DOI: 10.1136/bmjopen-2013-004158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
358 Halpern B, Daher G, Halpern A. Medical Management of Obesity. Endocrinology and Diabetes 2014. [DOI: 10.1007/978-1-4614-8684-8_41] [Reference Citation Analysis]
359 Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86. [PMID: 24231879 DOI: 10.1001/jama.2013.281361] [Cited by in Crossref: 558] [Cited by in F6Publishing: 583] [Article Influence: 69.8] [Reference Citation Analysis]
360 Pasarica M, Smith SR. Drugs for Weight Loss and Maintenance: Present and Future. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-2311-3_16] [Reference Citation Analysis]
361 Fujishima Y, Maeda N. Effect of Glucagon-Like Peptide 1 Receptor Agonists on Visceral Fat Adiposity, Appetite, and Food Preference. Nutrition in the Prevention and Treatment of Abdominal Obesity 2014. [DOI: 10.1016/b978-0-12-407869-7.00015-5] [Reference Citation Analysis]
362 Bandeira F, Moura F, Costi BB. GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. Endocrinology and Diabetes 2014. [DOI: 10.1007/978-1-4614-8684-8_30] [Reference Citation Analysis]
363 González-jiménez E, Mullin GE. Obesity and Metabolic Syndrome: Etiopathogenic Analysis. Integrative Weight Management 2014. [DOI: 10.1007/978-1-4939-0548-5_5] [Reference Citation Analysis]
364 Bavec A. Insulin, Other Hypoglycaemic Drugs, and Glucagon. Side Effects of Drugs Annual 2014. [DOI: 10.1016/b978-0-444-63407-8.00042-3] [Reference Citation Analysis]
365 Pasarica M, Smith SR. Drugs for Weight Loss and Maintenance: Present and Future. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-1203-2_16] [Reference Citation Analysis]
366 Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014;3:241-251. [PMID: 24749050 DOI: 10.1016/j.molmet.2013.12.001] [Cited by in Crossref: 106] [Cited by in F6Publishing: 111] [Article Influence: 11.8] [Reference Citation Analysis]
367 Lean M, Brosnahan N, McLoone P, McCombie L, Higgs AB, Ross H, Mackenzie M, Grieve E, Finer N, Reckless J, Haslam D, Sloan B, Morrison D. Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. Br J Gen Pract 2013;63:e115-24. [PMID: 23561690 DOI: 10.3399/bjgp13X663073] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
368 Albrechtsen NJW, Kuhre RE, Deacon CF, Holst JJ. Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. Expert Review of Endocrinology & Metabolism 2013;9:61-72. [DOI: 10.1586/17446651.2014.862152] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
369 Thayer S, Wei W, Buysman E, Brekke L, Crown W, Grabner M, Raparla S, Quimbo R, Cziraky MJ, Hu W, Cuddihy R. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. Adv Ther 2013;30:1128-40. [PMID: 24293131 DOI: 10.1007/s12325-013-0074-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
370 Habegger KM, Heppner KM, Amburgy SE, Ottaway N, Holland J, Raver C, Bartley E, Müller TD, Pfluger PT, Berger J, Toure M, Benoit SC, Dimarchi RD, Perez-Tilve D, D'Alessio DA, Seeley RJ, Tschöp MH. GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. Diabetes 2014;63:505-13. [PMID: 24186863 DOI: 10.2337/db13-0511] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
371 Foghsgaard S, Vedtofte L, Mathiesen ER, Svare JA, Gluud LL, Holst JJ, Damm P, Knop FK, Vilsbøll T. The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open 2013;3:e003834. [PMID: 24176797 DOI: 10.1136/bmjopen-2013-003834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
372 Trevaskis JL, Mack CM, Sun C, Soares CJ, D'Souza LJ, Levy OE, Lewis DY, Jodka CM, Tatarkiewicz K, Gedulin B, Gupta S, Wittmer C, Hanley M, Forood B, Parkes DG, Ghosh SS. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLoS One 2013;8:e78154. [PMID: 24167604 DOI: 10.1371/journal.pone.0078154] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
373 Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci. 2013;7:181. [PMID: 24133407 DOI: 10.3389/fnins.2013.00181] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 11.1] [Reference Citation Analysis]
374 Alssema M, Rijkelijkhuizen JM, Holst JJ, Teerlink T, Scheffer PG, Eekhoff EMW, Gastaldelli A, Mari A, Hart LM, Nijpels G, Dekker JM. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. European Journal of Endocrinology 2013;169:421-30. [DOI: 10.1530/eje-13-0487] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
375 van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:784-793. [PMID: 23999198 DOI: 10.1038/ijo.2013.162] [Cited by in Crossref: 257] [Cited by in F6Publishing: 269] [Article Influence: 28.6] [Reference Citation Analysis]
376 Lapolla A, Dalfra MG. Prepregnancy weight optimization and care. Obesity & Pregnancy 2013. [DOI: 10.2217/ebo.13.547] [Reference Citation Analysis]
377 Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A; NN8022-1807 Investigators. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:689-97. [PMID: 23942319 DOI: 10.1038/ijo.2013.149] [Cited by in Crossref: 112] [Cited by in F6Publishing: 118] [Article Influence: 12.4] [Reference Citation Analysis]
378 Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443-1451. [PMID: 23812094 DOI: 10.1038/ijo.2013.120] [Cited by in Crossref: 406] [Cited by in F6Publishing: 424] [Article Influence: 45.1] [Reference Citation Analysis]
379 Habegger KM, Kirchner H, Yi CX, Heppner KM, Sweeney D, Ottaway N, Holland J, Amburgy S, Raver C, Krishna R, Müller TD, Perez-Tilve D, Pfluger PT, Obici S, DiMarchi RD, D'Alessio DA, Seeley RJ, Tschöp MH. GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. Diabetes 2013;62:3261-7. [PMID: 23775764 DOI: 10.2337/db13-0117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
380 Hainer V, Hainerová IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev 2012;28 Suppl 2:8-20. [PMID: 23280861 DOI: 10.1002/dmrr.2349] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
381 Kidambi S, Kotchen TA. Treatment of hypertension in obese patients. Am J Cardiovasc Drugs 2013;13:163-75. [PMID: 23579967 DOI: 10.1007/s40256-013-0008-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
382 Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today 2013;18:807-17. [PMID: 23726889 DOI: 10.1016/j.drudis.2013.05.011] [Cited by in Crossref: 512] [Cited by in F6Publishing: 440] [Article Influence: 56.9] [Reference Citation Analysis]
383 Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 2014;16:9-21. [DOI: 10.1111/dom.12119] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
384 Valensi P, Chiheb S, Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia 2013;56:1196-200. [PMID: 23584434 DOI: 10.1007/s00125-013-2909-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
385 Rizzo M, Nikolic D, Banach M, Giglio RV, Patti AM, Di Bartolo V, Tamburello A, Zabbara A, Pecoraro G, Montalto G, Rizvi AA. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective. Clinical Lipidology 2013;8:173-81. [DOI: 10.2217/clp.13.8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
386 Greer L, Landwehr K. Do Glucagon-Like Peptide-1 Analogs Affect Diabetic Compliance and Quality of Life? The Journal for Nurse Practitioners 2013;9:219-223. [DOI: 10.1016/j.nurpra.2013.01.008] [Reference Citation Analysis]
387 Gallwitz B. Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin? Drugs 2013;73:393-5. [DOI: 10.1007/s40265-013-0039-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
388 Journal of DiabetesNEWS. J Diabetes 2013;5:3-6. [DOI: 10.1111/1753-0407.12018] [Reference Citation Analysis]
389 Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab 2013;24:145-52. [PMID: 23415157 DOI: 10.1016/j.tem.2013.01.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
390 Jindal A, Whaley-Connell A, Brietzke S, Sowers JR. Therapy of obese patients with cardiovascular disease. Curr Opin Pharmacol 2013;13:200-4. [PMID: 23332347 DOI: 10.1016/j.coph.2012.12.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
391 Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013;37:1161-1168. [PMID: 23295502 DOI: 10.1038/ijo.2012.208] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 12.0] [Reference Citation Analysis]
392 Pedersen SD. Impact of Newer Medications for Type 2 Diabetes on Body Weight. Curr Obes Rep 2013;2:134-41. [DOI: 10.1007/s13679-012-0045-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
393 Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci 2013;36:133-40. [PMID: 23312373 DOI: 10.1016/j.tins.2012.12.001] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 8.7] [Reference Citation Analysis]
394 Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012;5:621-6. [PMID: 22915024 DOI: 10.1242/dmm.009621] [Cited by in Crossref: 302] [Cited by in F6Publishing: 311] [Article Influence: 33.6] [Reference Citation Analysis]
395 Vilsbøll T, Calanna S, Knop FK. The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome. The Metabolic Syndrome 2013. [DOI: 10.1007/978-3-7091-1331-8_12] [Reference Citation Analysis]
396 Ziegler O, Krempf M. Is the Adipose Tissue a Relevant Target for Obesity Treatment? Physiology and Physiopathology of Adipose Tissue 2013. [DOI: 10.1007/978-2-8178-0343-2_26] [Reference Citation Analysis]
397 Gathercole LL, Morgan SA, Tomlinson JW. Hormonal Regulation of Lipogenesis. Obesity. Elsevier; 2013. pp. 1-27. [DOI: 10.1016/b978-0-12-407766-9.00001-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
398 Cho YH, Lee SY. Food Intake and Gut Hormones. Korean J Obes 2013;22:197. [DOI: 10.7570/kjo.2013.22.4.197] [Reference Citation Analysis]
399 Ziegler O, Krempf M. Le tissu adipeux est-il une cible thérapeutique pertinente de l’obésité? Physiologie et physiopathologie du tissu adipeux 2013. [DOI: 10.1007/978-2-8178-0332-6_26] [Reference Citation Analysis]
400 Bewick GA. Bowels control brain: gut hormones and obesity. Biochem Med (Zagreb) 2012;22:283-97. [PMID: 23092061 DOI: 10.11613/bm.2012.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
401 Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013;9:17-29. [PMID: 23094590 DOI: 10.1517/17425255.2013.731394] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
402 Edwards KL, Stapleton M, Weis J, Irons BK. An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Technology & Therapeutics 2012;14:951-67. [DOI: 10.1089/dia.2012.0098.edw] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
403 Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol 2012;215:335-46. [PMID: 23019069 DOI: 10.1530/JOE-12-0368] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 9.1] [Reference Citation Analysis]
404 Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013;15:42-54. [PMID: 22862847 DOI: 10.1111/j.1463-1326.2012.01673.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
405 Nambu T, Matsuda Y, Matsuo K, Kanai Y, Yonemitsu S, Muro S, Oki S. Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin. J Diabetes Investig 2013;4:69-77. [PMID: 24843633 DOI: 10.1111/j.2040-1124.2012.00242.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
406 Wirth A. Beachtliche Gewichtsabnahme mit Antidiabetikum. CV 2012;12:75-75. [DOI: 10.1007/s15027-012-0227-8] [Reference Citation Analysis]
407 Ebdrup BH, Knop FK, Ishøy PL, Rostrup E, Fagerlund B, Lublin H, Glenthøj B. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 2012;10:92. [PMID: 22891821 DOI: 10.1186/1741-7015-10-92] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
408 Astrup A. Weight loss produced by gastric bypass surgery: more gut feelings hit the brain. The American Journal of Clinical Nutrition 2012;96:457-8. [DOI: 10.3945/ajcn.112.045179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
409 Hussain SS, Bloom SR. The regulation of food intake by the gut-brain axis: implications for obesity. Int J Obes (Lond) 2013;37:625-33. [PMID: 22710925 DOI: 10.1038/ijo.2012.93] [Cited by in Crossref: 129] [Cited by in F6Publishing: 133] [Article Influence: 12.9] [Reference Citation Analysis]
410 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. [PMID: 22683128 DOI: 10.1016/s0140-6736(12)60283-9] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1478] [Article Influence: 138.8] [Reference Citation Analysis]
411 Hauner H. Individuelle Therapieziele bei Diabetes und extremer Adipositas. Diabetologe 2012;8:127-30. [DOI: 10.1007/s11428-011-0820-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
412 Holst JJ. Incretin based therapies: Do they hold their promise?: Commentary. Journal of Diabetes 2012;4:4-7. [DOI: 10.1111/j.1753-0407.2012.00186.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
413 Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187-215. [PMID: 22323472 DOI: 10.1210/er.2011-1052] [Cited by in Crossref: 397] [Cited by in F6Publishing: 411] [Article Influence: 39.7] [Reference Citation Analysis]
414 Scheen A, Van Gaal L. Médicaments de l’obésité et risque cardiovasculaire. Médecine des Maladies Métaboliques 2012;6:31-37. [DOI: 10.1016/s1957-2557(12)70352-8] [Reference Citation Analysis]
415 Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9:209-222. [PMID: 22290234 DOI: 10.1038/nrcardio.2011.211] [Cited by in Crossref: 118] [Cited by in F6Publishing: 119] [Article Influence: 11.8] [Reference Citation Analysis]
416 Kim KS, Park SW. Drug Therapy for Obesity. Korean J Obes 2012;21:197. [DOI: 10.7570/kjo.2012.21.4.197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
417 Salem V, De Silva A, Matthews PM, Dhillo WS. Imaging the neuroendocrinology of appetite. Adipocyte 2012;1:68-72. [PMID: 23700513 DOI: 10.4161/adip.19021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
418 Bagger JI, Christensen M, Knop FK, Vilsbøll T. Therapy for obesity based on gastrointestinal hormones. Rev Diabet Stud 2011;8:339-47. [PMID: 22262071 DOI: 10.1900/RDS.2011.8.339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
419 Sam AH, Troke RC, Tan TM, Bewick GA. The role of the gut/brain axis in modulating food intake.Neuropharmacology. 2012;63:46-56. [PMID: 22037149 DOI: 10.1016/j.neuropharm.2011.10.008] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 9.7] [Reference Citation Analysis]
420 Wadden TA, Fujioka K, Toubro S, Gantz I, Erondu NE, Chen M, Suryawanshi S, Carofano W, Johnson-Levonas AO, Shapiro DR, Kaufman KD, Heymsfield SB, Amatruda JM. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity (Silver Spring) 2010;18:2301-10. [PMID: 20379151 DOI: 10.1038/oby.2010.67] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]